Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Dry Eye News

11/27/2024
AllergyBreakingCataractDry EyePharma
Harrow Lowers Price of Drugs through GoodRx Partnership, Price Cuts
Harrow Lowers Price of Drugs through GoodRx Partnership, Price Cuts

Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients without insurance or for whom insurance is not a viable option a cash-pay alt...

11/27/2024
BreakingDeviceDry EyeRegulation
US FDA Clears Tixel i Dry Eye and MGD Treatment Device from Novoxel
US FDA Clears Tixel i Dry Eye and MGD Treatment Device from Novoxel

Israel’s Novoxel announced Nov. 19 that the US FDA had granted 510(k) clearance to the Tixel i treatment device for evaporative dry eye and meibomian gland dysfunction. The company said the device ...

11/22/2024
BreakingCataractDry EyeLaserOcular CancerRevenue
Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix
Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix

UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...

11/22/2024
BreakingDry EyeRegulation
US FDA Accepts NDA for Aldeyra’s Reproxalap in Dry Eye
US FDA Accepts NDA for Aldeyra’s Reproxalap in Dry Eye

Aldeyra Therapeutics announced Nov. 18 that the US FDA had accepted for review the company’s resubmitted new drug application (NDA) for topical ocular reproxalap for dry eye. The FDA assigned a Pre...

11/15/2024
BreakingCataractChinaDry EyeGlaucomaIOLLaserRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex
Q3-2024 Ophthalmic Revenue Roundup for Alcon, Hoya, RxSight, Sight Sciences, and Iridex

Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...

11/14/2024
DiagnosticDry EyeNewsletter
ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform
ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform

ARPA-H announced Oct. 18 that it had launched a new program to develop a tear-based biomarker measurement system that can be inserted into the tear duct to provide continuous health monitoring, pai...

11/14/2024
DealsDry EyeNewsletter
NovaBay Accepts Higher Offer from PRN to Purchase Assets
NovaBay Accepts Higher Offer from PRN to Purchase Assets

NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...

11/14/2024
CataractClinical TrialDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIndustryInstrumentsMicroscopesNewsletterOCTPresbyopiaRegulationRetinaStudySurgical
November 2024 Ophthalmic News Briefs
November 2024 Ophthalmic News Briefs

Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...

11/8/2024
BreakingCataractCornealDry EyeGlaucomaLaserPharmaPresbyopiaRefractiveRetinaRevenueSurgical
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar

AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...

11/8/2024
BreakingDealsDry Eye
NovaBay Accepts Higher Offer from PRN to Purchase Assets
NovaBay Accepts Higher Offer from PRN to Purchase Assets

NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...

11/8/2024
BreakingDry EyeIndustry
Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officer
Tarsus Appoints Elizabeth Yeu, MD, as Chief Medical Officer

Tarsus Pharmaceuticals, maker of Xdemvy for Demodex blepharitis, announced Nov. 5 that it had appointed Elizabeth Yeu, MD, as chief medical officer. Yeu had served as Tarsus’ chief medical advisor ...

11/1/2024
BreakingDealsDry Eye
NovaBay Receives Higher Asset Purchase Bid from RVL-Affiliated Company
NovaBay Receives Higher Asset Purchase Bid from RVL-Affiliated Company

NovaBay reported Oct. 29 that it had received a better offer for its assets than the one it had accepted from PRN Physician Recommended Nutriceuticals, LLC. NovaBay’s board determined that the unso...

10/25/2024
BreakingDiagnosticDry EyeFundingStudy
ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform
ARPA-H Seeks Proposals for Tear Duct-Based Diagnostic System, Plus Custom Dosing Platform

ARPA-H announced Oct. 18 that it had launched a new program to develop a tear-based biomarker measurement system that can be inserted into the tear duct to provide continuous health monitoring, pai...

10/25/2024
BreakingCornealDealsDry EyeFundingStudy
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure
Grifols, BARDA Partner on Ocular Immunoglobulin Drops for Sulfur Mustard Exposure

Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...

10/15/2024
DiagnosticDry EyeEmergingLow VisionNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, October 2024
Emerging Companies Pursuing Ophthalmic Indications, October 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

10/15/2024
Clinical TrialCornealDry EyeGene TherapyGlaucomaIOLNewsletterOcular CancerRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

10/15/2024
ChinaClinical TrialDealsDiagnosticDry EyeEuropeGene TherapyGlaucomaIndiaIndustryLaserNewsletterPerimetryRegulationRetinaSurgical
October 2024 Ophthalmic News Briefs
October 2024 Ophthalmic News Briefs

Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...

10/15/2024
DealsDry EyeNewsletter
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan

NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRN Physician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close...

10/11/2024
BreakingDry EyeRegulation
Aldeyra Resubmits NDA for Reproxalap in Dry Eye
Aldeyra Resubmits NDA for Reproxalap in Dry Eye

Aldeyra Therapeutics announced Oct. 3 that it had resubmitted its new drug application (NDA) to the US FDA for topical ocular reproxalap in dry eye. The US FDA issued a complete response letter in ...

10/4/2024
BreakingDealsDry EyeEuropeRegulation
EU Regulators Approve Vevizye from Novaliq; Théa Will Commercialize Dry Eye Drop
EU Regulators Approve Vevizye from Novaliq; Théa Will Commercialize Dry Eye Drop

Germany’s Novaliq announced Oct. 2 that the European Commission had approved its dry eye treatment Vevizye (cyclosporine ophthalmic solution) 0.1%. The product is indicated for the treatment of mod...

9/20/2024
BreakingDealsDry Eye
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan
NovaBay to Sell Avenova Products for $9.5 Million as Part of Dissolution Plan

NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRNPhysician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close ...

9/20/2024
BreakingDry EyeRegulation
US FDA Warns Regener-Eyes Maker Over Plant Conditions, Unapproved Products
US FDA Warns Regener-Eyes Maker Over Plant Conditions, Unapproved Products

The US FDA has sent a warning letter to Regenerative Processing Plant in Palm Harbor, Florida, finding fault with its manufacturing processes and raising concerns that its eye drop products may sti...

9/19/2024
Dry EyeEmergingGene TherapyNewsletterRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, September 2024
Emerging Companies Pursuing Ophthalmic Indications, September 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

8/23/2024
BreakingDry EyePharmaRegulation
Eyenovia Plans to Seek US FDA Clearance for Gen-2 Optejet Microdoser
Eyenovia Plans to Seek US FDA Clearance for Gen-2 Optejet Microdoser

Eyenovia announced in its Q2-2024 financial results that it planned to seek marketing clearance for an advanced Gen-2 Optejet microdoser. Eyenovia, of New York, said production was expected to begi...

8/21/2024
ChinaDealsDry EyeNewsletterPharma
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for Equity Stake
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for Equity Stake

China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...

8/21/2024
DiagnosticDry EyeFundingGene TherapyLaserNewsletterRetina
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering
MeiraGTx Leads Latest Ophthalmic Fundraising with $50 Million Offering

MeiraGTx led recent ophthalmic fundraising efforts with a $50 million offering of ordinary shares as it moves forward with its extensive pipeline of gene therapy candidates. Financing announced in ...

8/21/2024
Clinical TrialDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2024
Clinical Trial Updates for Ophthalmic Candidates, August 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

8/21/2024
CornealDry EyeEmergingNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, August 2024
Emerging Companies Pursuing Ophthalmic Indications, August 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

8/21/2024
Dry EyeGlaucomaNewsletter
USC Alums Gift Eye Care Practice to Roski Eye Institute
USC Alums Gift Eye Care Practice to Roski Eye Institute

Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...

8/21/2024
Dry EyeNewsletter
Weekly Surgeon Poll, August 2024
Weekly Surgeon Poll, August 2024

8/21/2024
BiosimilarsCornealDealsDry EyeEuropeGene TherapyGenericsIndustryLow VisionNewsletterOcular CancerPharmaPresbyopiaRegulationRetina
August 2024 Ophthalmic News Briefs
August 2024 Ophthalmic News Briefs

Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...

8/16/2024
BreakingChinaDealsDry EyePharma
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for 16.7 Percent Equity Stake
Ocumension Acquires Rights to Alcon Eye Drops in Exchange for 16.7 Percent Equity Stake

China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...

8/16/2024
BiosimilarsBreakingCataractDiagnosticDry EyeGlaucomaLaserOcular CancerRefractiveRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec,  Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex

AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....

8/9/2024
BreakingCataractDry EyeGlaucomaIOLRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint
Q2-2024 Ophthalmic Revenue Roundup for Hoya, Harrow, RxSight, Sight Sciences, Ocular Therapeutix, and EyePoint

Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...

8/9/2024
BreakingDry EyeGlaucoma
USC Alums Gift Eye Care Practice to Roski Eye Institute
USC Alums Gift Eye Care Practice to Roski Eye Institute

Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...

8/9/2024
BreakingCataractDealsDry EyePharmaSurgical
Formosa Licenses Clobetasol Propionate Drops to Apotex for Canada
Formosa Licenses Clobetasol Propionate Drops to Apotex for Canada

Taiwan-based Formosa Pharmaceuticals announced Aug. 5 that it had agreed to license to Apotex exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain...

8/2/2024
BreakingCornealDiagnosticDry EyeGlaucomaIOLLaserRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others
Q2-2024 Ophthalmic Revenue Roundup for Regeneron, Roche, Bausch + Lomb, Novartis, and Four Others

Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...

8/2/2024
BiosimilarsBreakingDry EyeEuropeRegulationRetina
Novaliq Receives Positive CHMP Opinion for Vevizye in Dry Eye
Novaliq Receives Positive CHMP Opinion for Vevizye in Dry Eye

Germany’s Novaliq announced July 29 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for Vevi...

8/2/2024
BreakingDealsDry Eye
Eyenovia, SGN Nanopharma Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser
Eyenovia, SGN Nanopharma Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser

Eyenovia, of New York, announced July 30 that it had entered into a collaboration agreement with SGN Nanopharma to develop SGN’s micellar nanoparticle platform-based cyclosporine formulation for us...

7/26/2024
BreakingCornealDealsDiagnosticDry EyeSurgical
Bausch + Lomb Acquires Dry Eye Diagnostic Company Trukera Medical
Bausch + Lomb Acquires Dry Eye Diagnostic Company Trukera Medical

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/26/2024
BreakingCornealDealsDry EyeIndustry
Eyenovia, Senju Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser
Eyenovia, Senju Will Collaborate on Chronic Dry Eye Candidate with Optejet Microdoser

Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...

7/26/2024
AllergyBreakingDry Eye
New OTC Eye Lubricants Available from AbbVie, Ocusoft
New OTC Eye Lubricants Available from AbbVie, Ocusoft

AbbVie has introduced two new preservative-free lubricant eye drop products—Refresh Tears PF and Refresh Relieva PF Xtra. AbbVie, of North Chicago, Illinois, said the new products feature a soft-sq...

7/23/2024
Dry EyeNewsletter
Bausch + Lomb Adds Dry Eye Supplement to Fast-Growing Consumer Segment
Bausch + Lomb Adds Dry Eye Supplement to Fast-Growing Consumer Segment

Bausch + Lomb is expanding its fast-growing consumer segment with the launch of a nutritional supplement to combat the signs and symptoms of dry eye. The supplement is called Blink NutriTears. The ...

7/23/2024
Clinical TrialDry EyeGene TherapyIOLNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2024
Clinical Trial Updates for Ophthalmic Candidates, July 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

7/23/2024
BiosimilarsClinical TrialCornealDealsDry EyeEuropeGene TherapyGlaucomaIndiaIndustryMyopiaNewsletterRegulationRetina
July 2024 Ophthalmic News Briefs
July 2024 Ophthalmic News Briefs

Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...

7/19/2024
BreakingClinical TrialCornealDry Eye
Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain
Okyo Pharma to Initiate Phase II Trial for OK-101 in Neuropathic Corneal Pain

London’s Okyo Pharma announced July 11 that it would advance OK-101 into a Phase II clinical trial of neuropathic corneal pain (NCP). The US FDA cleared the investigational new drug (IND) applicati...

7/5/2024
BreakingDealsDry Eye
Kane Biotech Licenses Biofilm Dispersion Enzyme to I-Med for Dry Eye
Kane Biotech Licenses Biofilm Dispersion Enzyme to I-Med for Dry Eye

Kane Biotech announced June 25 that I-Med Pharma had licensed its DispersinB biofilm dispersion technology to incorporate into its products to relieve dry eye. It’s the first commercial agreement f...

6/24/2024
Dry EyeNewsletter
Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye in US
Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye in US

Nordic Pharma announced May 29 that it had launched Lacrifill canalicular gel for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative intended to temporarily block tear draina...

6/24/2024
CornealDry EyeNewsletter
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders

BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...

6/24/2024
CataractClinical TrialDry EyeNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, June 2024
Clinical Trial Updates for Ophthalmic Candidates, June 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

6/24/2024
CataractClinical TrialData SecurityDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryMyopiaNewsletterRefractiveRegulationRetinaSurgical
June 2024 Ophthalmic News Briefs
June 2024 Ophthalmic News Briefs

Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...

6/14/2024
BreakingCornealDry Eye
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders
BioTissue Introduces Shelf-Stable CAM360 AmnioGraft for Dry Eye, Other Disorders

BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...

6/7/2024
BreakingDry Eye
Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye in US
Nordic Pharma Launches Lacrifill Canalicular Gel for Dry Eye in US

Nordic Pharma announced May 29 that it had launched Lacrifill canalicular gel for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative intended to temporarily block tear draina...

5/31/2024
BreakingDry EyeRegulation
Santen Recalls All Unexpired Lots of Diquas LX Over Issues with Preservative
Santen Recalls All Unexpired Lots of Diquas LX Over Issues with Preservative

Santen has issued a voluntary recall and suspended shipment for all unexpired lots of its dry eye treatment Diquas LX in Japan due to issues with a preservative, Pharma Japan reported May 23. Sante...

5/24/2024
BiosimilarsBreakingDry EyeGlaucomaLaserRetinaRevenue
Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen
Q1-2024 Ophthalmic Revenue Roundup for AbbVie, Iridex, and Biogen

AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...

5/22/2024
CornealDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterOcular CancerRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Emerging Companies Pursuing Ophthalmic Indications, May 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

5/22/2024
CataractChinaCornealDiagnosticDry EyeGlaucomaIndiaMicroscopesNewsletterPharmaRegulationRetina
May 2024 Ophthalmic News Briefs
May 2024 Ophthalmic News Briefs

Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...

5/17/2024
BreakingDiagnosticDry EyePharmaRetinaRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, and Harrow
Q1-2024 Ophthalmic Revenue Roundup for Alcon, Carl Zeiss Meditec, and Harrow

Alcon reported May 13 that its Q1-2024 net sales were $2.4 billion, a 5 percent increase (+7 percent cc) over $2.3 billion in Q1-2023. Surgical net sales totaled $1.34 billion, consisting of $433 m...

5/10/2024
BreakingCataractDry EyeGlaucomaRefractiveRetinaRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others
Q1-2024 Ophthalmic Revenue Roundup for Apellis, STAAR, RxSight, Tarsus, Sight Sciences, and Three Others

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...

5/10/2024
BreakingDiagnosticDry EyeEurope
Lumibird Launches C.Diag Diagnostic Platform for Dry Eye
Lumibird Launches C.Diag Diagnostic Platform for Dry Eye

France’s Lumibird Medical announced May 3 that it had launched C.Diag, a dry eye diagnostic imaging platform incorporating artificial intelligence, after gaining the European Union’s CE marking for...

5/3/2024
BreakingCataractDry EyeGlaucomaLaserRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird
Q1-2024 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, and Lumibird

Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...

4/24/2024
ASCRSCataractDry EyeNewsletterRefractiveSurgical
Dry Eye Screening Before Surgery Seems Logical, but Hurdles Remain
Dry Eye Screening Before Surgery Seems Logical, but Hurdles Remain

The need to continue lobbying for dry eye evaluation prior to patients undergoing anterior segment surgery is somewhat baffling. Such testing seems like an obvious approach for the many patients wh...

4/24/2024
ASCRSDry EyeEyeceleratorNewsletterPharmaRegulation
Eyecelerator Celebrates Fourth Anniversary While Showcasing Innovation in Ophthalmology
Eyecelerator Celebrates Fourth Anniversary While Showcasing Innovation in Ophthalmology

A nor’easter storm that disrupted many travel itineraries failed to deter the nearly 600 industry personnel and clinicians who attended Eyecelerator ahead of the 2024 ASCRS meeting. This year’s con...

4/24/2024
Clinical TrialCornealData SecurityDealsDiagnosticDry EyeEnvironmentFundingGlaucomaIOLIndustryMicroscopesNewsletterRegulationRetina
April 2024 Ophthalmic News Briefs
April 2024 Ophthalmic News Briefs

Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...

4/5/2024
BreakingClinical TrialDry Eye
Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye
Aldeyra Outlines New Reproxalap Trial, Aims to Resubmit NDA in Dry Eye

Aldeyra Therapeutics on March 28 outlined its new clinical development plan for reproxalap eye drops, with the goal of resubmitting its new drug application (NDA) to the US FDA. The company said it...

3/29/2024
BreakingDry EyeGlaucomaLaserRevenue
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay
2023 Ophthalmic Revenue Roundup for Iridex and NovaBay

Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...

3/29/2024
BreakingClinical TrialDry Eye
Okyo’s Dry Eye Candidate Hits Multiple Phase II Endpoints, Including Ocular Pain Relief
Okyo’s Dry Eye Candidate Hits Multiple Phase II Endpoints, Including Ocular Pain Relief

London’s Okyo Pharma released additional findings on March 22 from its Phase II trial of topical dry eye candidate OK-101. The company had previously reported statistically significant improvements...

3/22/2024
BreakingDealsDry EyePharmaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Harrow, Alimera Sciences, and EyePoint
2023 Ophthalmic Revenue Roundup for Harrow, Alimera Sciences, and EyePoint

Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...

3/22/2024
BreakingDry EyeIndustry
Amring Adopts Name Nordic Pharma Amid Ownership Change
Amring Adopts Name Nordic Pharma Amid Ownership Change

Amring Pharmaceuticals announced March 4 that it had changed its name to Nordic Pharma Inc., following the change in ownership of the company from Sever Life Sciences to Nordic Group in June 2023. ...

3/21/2024
Dry EyeNewsletterRegulation
Eye Ointments Sold at Walmart, CVS Recalled Due to Infection Risk
Eye Ointments Sold at Walmart, CVS Recalled Due to Infection Risk

India’s Brassica Pharma announced Feb. 12 that it was voluntarily recalling eye ointments sold by retailers such as Walmart and CVS due to a danger of infection. The company said an inspection by t...

3/21/2024
Clinical TrialDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, March 2024
Clinical Trial Updates for Ophthalmic Candidates, March 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

3/21/2024
DiagnosticDry EyeFundingNewsletterRetina
Ocular Tx Leads Latest Ophthalmic Fundraising with $325 Million Private Placement
Ocular Tx Leads Latest Ophthalmic Fundraising with $325 Million Private Placement

Ocular Therapeutix led recent ophthalmic fundraising efforts with a $325 million private placement to advance its candidate for wet age-related macular degeneration. Financing announced in the past...

3/21/2024
CornealDealsDry EyeIOLIndustryNewsletterRegulationRetina
March 2024 Ophthalmic News Briefs
March 2024 Ophthalmic News Briefs

Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...

3/21/2024
Dry EyeNewsletterRegulation
Weekly Surgeon Poll, March 2024
Weekly Surgeon Poll, March 2024

3/21/2024
AllergyDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, March 2024
Emerging Companies Pursuing Ophthalmic Indications, March 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

3/15/2024
BreakingCataractDry EyeGlaucomaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix
2023 Ophthalmic Revenue Roundup for Sight Sciences and Ocular Therapeutix

Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...

3/15/2024
BreakingCataractDealsDry EyePharma
NovaBay, Eyenovia Team Up to Co-promote Ophthalmic Products
NovaBay, Eyenovia Team Up to Co-promote Ophthalmic Products

Eyenovia and NovaBay Pharmaceuticals announced March 13 the signing of a co-promotion agreement to commercialize their prescription ophthalmic products. Under the agreement, NovaBay will market Eye...

3/15/2024
BreakingDry EyeIndustry
Richard Lindstrom, MD, Becomes Chairman of Surface Ophthalmics
Richard Lindstrom, MD, Becomes Chairman of Surface Ophthalmics

Surface Ophthalmics, of Pleasanton, California, has named co-founder and director Richard Lindstrom, MD, as chairman. The company, which is developing dry eye drugs, was formed in 2018. Lindstrom w...

3/15/2024
BreakingCornealDry EyeIndustry
Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officer
Vital Tears Appoints Joseph Tauber, MD, as Chief Medical Officer

Vital Tears announced March 6 that it had appointed Joseph Tauber, MD, as its chief medical officer. In 2023, Vital Tears added mobile phlebotomy services to its system of providing autologous seru...

3/8/2024
BreakingDry EyeFunding
Tarsus Prices $100 Million Public Offering
Tarsus Prices $100 Million Public Offering

Tarsus Pharmaceuticals, of Irvine, California, announced March 1 that it had priced an underwritten public offering of shares and warrants, with expected gross proceeds of $100 million. Goldman Sac...

3/1/2024
BreakingCornealDry EyeGlaucomaIOLRefractiveRetinaRevenueSurgical
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus
2023 Ophthalmic Revenue Roundup for Alcon, Bausch + Lomb, STAAR, Glaukos, Apellis, and Tarsus

Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...

3/1/2024
BreakingDry EyeIndiaRegulation
Eye Ointments Sold at Walmart, CVS Recalled Due to Infection Risk
Eye Ointments Sold at Walmart, CVS Recalled Due to Infection Risk

India’s Brassica Pharma announced Feb. 12 that it was voluntarily recalling eye ointments sold by retailers such as Walmart and CVS due to a danger of infection. The company said an inspection by t...

2/22/2024
ChinaDry EyeIndustryNewsletter
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets

Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...

2/22/2024
Clinical TrialDry EyeNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates , February 2024
Clinical Trial Updates for Ophthalmic Candidates , February 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

2/22/2024
CataractClinical TrialCornealDealsDiagnosticDry EyeGene TherapyGlaucomaIOLIndustryNewsletterPresbyopiaRegulationRetinaSurgical
February 2024 Ophthalmic News Briefs
February 2024 Ophthalmic News Briefs

Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...

2/16/2024
AllergyBreakingDealsDry EyePharmaSurgical
Harrow Licenses Rights to Five Drugs to Apotex for Canada
Harrow Licenses Rights to Five Drugs to Apotex for Canada

Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will p...

2/16/2024
BreakingDry EyeIndustry
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets

Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...

2/16/2024
BreakingClinical TrialDry Eye
Sylentis’ Topical Candidate for Sjögren’s Dry Eye Misses Endpoints in Phase III
Sylentis’ Topical Candidate for Sjögren’s Dry Eye Misses Endpoints in Phase III

Spain’s Sylentis, a PharmaMar Group company, announced Feb. 9 that tivanisiran, a topical treatment candidate for dry eye disease associated with Sjögren’s syndrome, did not meet primary efficacy e...

2/9/2024
BreakingDry EyeRetinaRevenue
2023 Ophthalmic Revenue Roundup for Regeneron, AbbVie, Amgen, and Astellas
2023 Ophthalmic Revenue Roundup for Regeneron, AbbVie, Amgen, and Astellas

Regeneron, of Tarrytown, New York, reported Feb. 2 that its 2023 US revenue for Eylea 2 mg (aflibercept 2 mg) and Eylea HD (aflibercept 8 mg) totaled $5.9 billion, a 6 percent decline from $6.3 bil...

1/23/2024
Dry EyeIOLNewsletterRefractive
2023 in Review: Bausch + Lomb Makes Big Moves, Adding Product Lines and Building Partnerships
2023 in Review: Bausch + Lomb Makes Big Moves, Adding Product Lines and Building Partnerships

Bausch + Lomb made a flurry of big moves in 2023, with product approvals, acquisitions, leadership changes, and strategic partnerships and collaborations following the company’s IPO in mid-2022. In...

1/23/2024
Dry EyeIOLLaserNewsletterRegulation
Select US FDA Approvals and Clearances in December 2023
Select US FDA Approvals and Clearances in December 2023

The US FDA granted five clearances through the ophthalmic device division using the 510(k) pathway in December 2023, according to the agency’s database. RetMap gained market clearance for its RM El...

1/23/2024
CataractClinical TrialDry EyeGene TherapyGlaucomaNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, January 2024
Clinical Trial Updates for Ophthalmic Candidates, January 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

1/23/2024
Dry EyeNewsletterRegulation
2023 in Review: US FDA Cracks Down on OTC Eye Drops Amid Fatal Infections
2023 in Review: US FDA Cracks Down on OTC Eye Drops Amid Fatal Infections

Makers of over-the-counter eye drops came under increased surveillance from the US FDA in 2023, in part because contaminated products manufactured in India caused at least 81 people to become infec...

1/23/2024
Dry EyeNewsletterPharma
2023 in Review: Two Drugs with New Mode of Action Mark Upheaval in Dry Eye
2023 in Review: Two Drugs with New Mode of Action Mark Upheaval in Dry Eye

The US FDA approved a new class of drugs to treat the signs and symptoms of dry eye disease in 2023. Two new treatments in the class, Miebo and Vevye, are both based on perfluorocarbon (PFC) molecu...

1/23/2024
Clinical TrialDry EyeNewsletter
Alcon Reports Positive Topline Results in Phase III for AR-15512 in Dry Eye
Alcon Reports Positive Topline Results in Phase III for AR-15512 in Dry Eye

Alcon reported Jan. 9 that it saw positive topline results from two pivotal Phase III clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512 in dry eye. AR-15512, a TR...

1/23/2024
CornealDry EyeFundingNewsletterPresbyopiaRetina
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round

China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...

1/23/2024
CataractCornealDealsDry EyeGene TherapyGlaucomaIndustryLaserNewsletterOCTRegulationRetina
January 2024 Ophthalmic News Briefs
January 2024 Ophthalmic News Briefs

Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...

1/12/2024
BreakingDry EyePharma
Harrow Launches Dry Eye Drug Vevye in US
Harrow Launches Dry Eye Drug Vevye in US

Harrow, of Nashville, Tennessee, reported Jan. 11 that dry eye drugVevye is now available in the US. Vevye (cyclosporine ophthalmic solution) 0.1% is a non‑preserved, twice-daily-dosed prescription...

1/12/2024
BreakingClinical TrialDry Eye
Alcon Reports Positive Topline Results in Phase III for AR-15512 in Dry Eye
Alcon Reports Positive Topline Results in Phase III for AR-15512 in Dry Eye

Alcon reported Jan. 9 that it saw positive topline results from two pivotal Phase III clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512 in dry eye. AR-15512, a TR...

1/5/2024
BreakingDealsDry Eye
Nordic Pharma Subsidiary Acquires Visant Medical, Will Launch Lacrifill for Dry Eye in US
Nordic Pharma Subsidiary Acquires Visant Medical, Will Launch Lacrifill for Dry Eye in US

Nordic Pharma subsidiary Amring Pharmaceuticals announced Dec. 18 that it had completed its acquisition of Visant Medical. Visant received US FDA 510(k) clearance in 2022 for its Lacrifill cross-li...

12/20/2023
BreakingClinical TrialDry Eye
Tarsus Reports Positive Topline Results from Phase IIa Trial of TP-03 for MGD with Demodex
Tarsus Reports Positive Topline Results from Phase IIa Trial of TP-03 for MGD with Demodex

Tarsus Pharmaceuticals, of Irvine, California, reported Dec. 11 that TP-03 (lotilaner ophthalmic solution, 0.25%) saw positive topline results in the Phase IIa Ersa trial of patients with meibomian...

12/14/2023
Clinical TrialDry EyeNewsletterRegulation
US FDA Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for New Trial to Show Symptom Relief
US FDA Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for New Trial to Show Symptom Relief

Aldeyra Therapeutics reported Nov. 27 that the US FDA had, as expected, issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment fo...

12/14/2023
Dry EyeNewsletterRegulation
FDA Report Details Problems Found at Indian Manufacturer of Recalled OTC Eye Drops in US
FDA Report Details Problems Found at Indian Manufacturer of Recalled OTC Eye Drops in US

The US FDA has released its preliminary report of an inspection conducted Oct. 12-20 at Kilitch Healthcare India, manufacturer of 27 over-the-counter eye drop products that were recalled Nov. 13 du...

12/14/2023
Clinical TrialDry EyeGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, December 2023
Clinical Trial Updates for Ophthalmic Candidates, December 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

12/14/2023
Dry EyeGlaucomaNewsletterPharmaPresbyopiaRegulationRetina
FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More
FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More

2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...

12/1/2023
BreakingClinical TrialDry EyeRegulation
US FDA Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for New Trial to Show Symptom Relief
US FDA Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for New Trial to Show Symptom Relief

Aldeyra Therapeutics reported Nov. 27 that the US FDA had, as expected, issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment fo...

12/1/2023
BreakingDry EyeIndiaRegulation
US FDA Report Details Problems Found at Indian Manufacturer of Recalled OTC Eye Drops
US FDA Report Details Problems Found at Indian Manufacturer of Recalled OTC Eye Drops

The US FDA has released its preliminary report of an inspection conducted Oct. 12-20 at Kilitch Healthcare India, manufacturer of 27 over-the-counter eye drop products that were recalled Nov. 13 du...

11/22/2023
BreakingDry EyeRegulation
Amazon Removes Seven Eye Drop Products After FDA Warning
Amazon Removes Seven Eye Drop Products After FDA Warning

Online retailer Amazon has removed seven eye drop products from its site after the US FDA warned the company that the products were unapproved drugs, making claims to relieve conjunctivitis or floa...

11/21/2023
Dry EyeNewsletter
New Products, Shift to Generic Cyclosporine Expected to Shake Up Slumping Dry Eye Market
New Products, Shift to Generic Cyclosporine Expected to Shake Up Slumping Dry Eye Market

Dry eye revenue continues to fall in the US this year, despite new products, as generic cyclosporine ophthalmic solutions and emulsions increase market share at the expense of brand name Restasis. ...

11/21/2023
CornealDiagnosticDry EyeFundingGlaucomaNewsletterRetina
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A
EyeBio Leads Latest Ophthalmic Fundraising with $65 Million in Series A

EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...

11/21/2023
AAODiagnosticDigitalDry EyeGlaucomaMeetingNewsletterRefractiveRegulationRetinaSurgical
Buzzworthy Topics at the 2023 AAO Meeting
Buzzworthy Topics at the 2023 AAO Meeting

Dry Eye: New products kept generating buzz around dry eye. Bausch + Lomb leaned into the promotion of Miebo, the new, first-in-class drug therapy that directly targets tear evaporation. Diagnostic ...

11/21/2023
AAODigitalDry EyeEyeceleratorGlaucomaMeetingNewsletterRetina
Eyecelerator at AAO Showcases Innovators and Awards $45 Thousand in Prize Money
Eyecelerator at AAO Showcases Innovators and Awards $45 Thousand in Prize Money

Eyecelerator awarded a total of $45 thousand in prize money to winning pitch challengers at its fall meeting, after emerging companies got a chance to work with accomplished industry veterans to re...

11/21/2023
DealsDry EyeNewsletterPharma
AbbVie Signs Option Deal with Aldeyra for License to Develop Reproxalap
AbbVie Signs Option Deal with Aldeyra for License to Develop Reproxalap

Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...

11/21/2023
Dry EyeNewsletterRegulation
FDA Warns of Possible Bacterial Contamination in 27 OTC Eye Drop Products
FDA Warns of Possible Bacterial Contamination in 27 OTC Eye Drop Products

The US FDA issued a warning to consumers Oct. 27 to immediately stop using more than two dozen over-the-counter eye drop products due to the potential risk of blinding eye infections. The products ...

11/21/2023
ChinaDealsDiagnosticDry EyeGene TherapyGenericsGlaucomaIndustryNewsletterPresbyopiaRegulationRetinaSurgical
November 2023 Ophthalmic News Briefs
November 2023 Ophthalmic News Briefs

Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...

11/17/2023
BreakingCataractDry EyeIOLOcular CancerPharmaRevenue
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others

UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...

11/10/2023
BreakingDry EyeGlaucomaIOLLaserRevenue
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix
Q3-2023 Ophthalmic Revenue Roundup for Hoya, Lumibird, Sight Sciences, and Ocular Therapeutix

Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...

11/3/2023
BreakingDry EyeGlaucomaPharmaRefractiveRetinaRevenueSurgical
Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch + Lomb, AbbVie, and Five Others
Q3-2023 Ophthalmic Revenue Roundup for Regeneron, Bausch +  Lomb, AbbVie, and Five Others

Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...

11/3/2023
BreakingDealsDry Eye
AbbVie Signs Option Agreement with Aldeyra for License to Develop and Commercialize Reproxalap
AbbVie Signs Option Agreement with Aldeyra for License to Develop and Commercialize Reproxalap

Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...

11/3/2023
BreakingDry EyeRegulation
US FDA Warns of Possible Bacterial Contamination in 27 Over-the-Counter Eye Drop Products
US FDA Warns of Possible Bacterial Contamination in 27 Over-the-Counter Eye Drop Products

The US FDA issued a warning to consumers Oct. 27 to immediately stop using more than two dozen over-the-counter eye drop products due to the potential risk of blinding eye infections. The products ...

11/3/2023
BreakingDry Eye
Bruder Introduces Air-Activated Moist Heat Eyedration Mask for Dry Eye Relief
Bruder Introduces Air-Activated Moist Heat Eyedration Mask for Dry Eye Relief

Bruder Healthcare, of Alpharetta, Georgia, announced Oct. 20 that it had added a single-use, air-activated moist heat mask to its line of dry eye relief products. Bruder said the Eyedration mask be...

10/27/2023
BiologicsBreakingDry EyeGlaucomaPharmaRetinaRevenueSurgical
Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox
Q3-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Nicox

Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...

10/24/2023
DealsDry EyeGene TherapyNewsletter
Acquisitions and OUS Investments Drive Ophthalmic Deals in Third Quarter of 2023
Acquisitions and OUS Investments Drive Ophthalmic Deals in Third Quarter of 2023

Ophthalmic deals in Q3-2023 reached nearly $2.8 billion and involved 22 transactions. This compares with $6.9 billion from 24 transactions in Q2-2023 and $1.0 billion from 20 transactions in Q3-202...

10/24/2023
DiagnosticDry EyeFundingNewsletter
Tilak Leads Latest Ophthalmic Fundraising with $10.6 Million Round
Tilak Leads Latest Ophthalmic Fundraising with $10.6 Million Round

France’s Tilak Healthcare led recent ophthalmic fundraising efforts with a $10.6 million funding round for its medical video games for chronic vision disorders. Financing announced in the past four...

10/24/2023
CataractDry EyeESCRSGlaucomaIOLMeetingNewsletterRegulationSurgical
Buzzworthy Topics at the 2023 ESCRS Congress
Buzzworthy Topics at the 2023 ESCRS Congress

Minimally Invasive Glaucoma Surgery (MIGS): The ESCRS highlighted the growing importance of MIGS this year by holding the meeting’s first MIGS master class. Several speakers in other sessions extol...

10/24/2023
Clinical TrialDry EyeGene TherapyNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2023
Clinical Trial Updates for Ophthalmic Candidates, October 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

10/24/2023
CataractClinical TrialDealsDiagnosticDry EyeGene TherapyGenericsIOLIndustryMicroscopesNewsletterOcular CancerRegulationRetina
October 2023 Ophthalmic News Briefs
October 2023 Ophthalmic News Briefs

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

10/24/2023
ChinaDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, October 2023
Emerging Companies Pursuing Ophthalmic Indications, October 2023

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

10/20/2023
BreakingDry EyeGlaucomaIndustryRegulation
Sight Sciences to Cut 25 Employees as it Awaits MACs’ Coverage Decision
Sight Sciences to Cut 25 Employees as it Awaits MACs’ Coverage Decision

Sight Sciences, of Menlo Park, California, has informed its employees that it will cut its workforce of 250 by 25 employees as it awaits a final decision by five of the seven Medicare Administrativ...

10/20/2023
BreakingDry EyeRegulation
US FDA Finds ‘Substantive’ Issues with Aldeyra’s NDA for Reproxalap in Dry Eye
US FDA Finds ‘Substantive’ Issues with Aldeyra’s NDA for Reproxalap in Dry Eye

Aldeyra Therapeutics reported in a securities filing on Oct. 16 that the US FDA had found “substantive” issues with the company’s new drug application (NDA) for topical dry eye candidate reproxalap...

10/20/2023
BreakingDry Eye
Merakris Unveils Nationwide At-Your-Door Autologous Serum Tears Program
Merakris Unveils Nationwide At-Your-Door Autologous Serum Tears Program

Merakris Therapeutics unveiled its Opticyte Tears program on Oct. 12—offering to deliver personalized autologous serum tears in less than two hours, without patients ever having to leave home. Mera...

9/29/2023
BreakingChinaDealsDry EyeEurope
CS Pharmaceuticals acquires AxeroVision and Cream-Based Dry Eye Candidate
CS Pharmaceuticals acquires AxeroVision and Cream-Based Dry Eye Candidate

London-based CS Pharmaceuticals reported July 28 that it had acquired AxeroVision, of Carlsbad, California, and its AXR-270 candidate for dry eye disease. The company did not report financial detai...

9/22/2023
BreakingCataractDry EyeGlaucomaIndustryPharma
Mati Completes Facility to Manufacture Evolute Punctal Plug Portfolio
Mati Completes Facility to Manufacture Evolute Punctal Plug Portfolio

Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...

9/21/2023
Dry EyeNewsletter
Bausch + Lomb Launches Dry Eye Drop Miebo in the US
Bausch + Lomb Launches Dry Eye Drop Miebo in the US

Bausch + Lomb announced Sept. 12 the US launch of Miebo (perfluorohexyloctane ophthalmic solution) for dry eye disease. The US FDA approved Miebo in May for dosing four times daily. Bausch + Lomb a...

9/21/2023
CataractDry EyeGlaucomaNewsletterRegulation
FDA Warns Eight Companies Over Marketing Unapproved or Unsafe Eye Drops in the US
FDA Warns Eight Companies Over Marketing Unapproved or Unsafe Eye Drops in the US

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

9/21/2023
CataractCornealDry EyeFundingGene TherapyNewsletterPharmaRetina
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue
Brim Leads Latest Ophthalmic Fundraising with $45.8 Million Rights Issue

Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...

9/21/2023
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, September 2023
Clinical Trial Updates for Ophthalmic Candidates, September 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

9/21/2023
ChinaClinical TrialCornealDealsDiagnosticDry EyeEuropeGene TherapyIndustryNewsletterRefractiveRegulationRetinaSurgical
September 2023 Ophthalmic News Briefs
September 2023 Ophthalmic News Briefs

Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...

9/15/2023
BreakingDry Eye
Bausch + Lomb Launches Dry Eye Drop Miebo in the US
Bausch + Lomb Launches Dry Eye Drop Miebo in the US

Bausch + Lomb announced Sept. 12 the US launch of Miebo (perfluorohexyloctane ophthalmic solution) for dry eye disease. The US FDA approved Miebo in May for dosing four times daily. Bausch + Lomb a...

9/15/2023
BreakingCataractDry EyeGlaucomaRegulation
FDA Warns Eight Companies Over Marketing Unapproved Eye Drops
FDA Warns Eight Companies Over Marketing Unapproved Eye Drops

The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...

9/15/2023
BreakingDealsDry Eye
Link Biologics Partners with Théa Open Innovation to Develop Dry Eye Candidate
Link Biologics Partners with Théa Open Innovation to Develop Dry Eye Candidate

Link Biologics, of London, and France’s Théa Open Innovation announced Sept. 12 that they had agreed to co-develop Link’s topical anti-inflammatory candidate TSG6 for dry eye disease and other opht...

9/8/2023
BreakingDry EyeRevenue
Viatris Reports Q2-2023 Tyrvaya Net Sales of $10.2 Million
Viatris Reports Q2-2023 Tyrvaya Net Sales of $10.2 Million

Viatris, of Pittsburgh, reported Aug. 7 that its Tyrvaya nasal spray for dry eye accounted for net sales of $10.2 million in Q2-2023. The prescription treatment posted net sales of $6.3 million in ...

9/1/2023
BreakingDry EyeRegulation
FDA Warns of Contamination in Certain MSM Eye Drops; Brand is Recalled
FDA Warns of Contamination in Certain MSM Eye Drops; Brand is Recalled

The US FDA issued a warning on Aug. 22 telling consumers not to purchase and to immediately stop using Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops—Eye Repair due to bacterial cont...

8/25/2023
BreakingDiagnosticDry EyePresbyopiaRetinaRevenueSurgical
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera

AbbVie, of North Chicago, Illinois, reported July 27 that Q2-2023 net revenue for its eye care products totaled $617 million, a 13.9 percent decline from $717 million in Q2-2022. Restasis revenue w...

8/25/2023
BreakingDry EyeEuropeRegulation
EMA Accepts Marketing Application for Dry Eye Candidate CyclASol from Novaliq
EMA Accepts Marketing Application for Dry Eye Candidate CyclASol from Novaliq

Novaliq, of Heidelberg, Germany, announced Aug. 24 that the European Medicines Agency (EMA) had accepted its marketing authorization application for dry eye candidate CyclASol (cyclosporine ophthal...

8/22/2023
Dry EyeNewsletterPharmaRegulation
US FDA Approves Xdemvy Eye Drops from Tarsus for Demodex Blepharitis
US FDA Approves Xdemvy Eye Drops from Tarsus for Demodex Blepharitis

Tarsus Pharmaceuticals announced July 25 that the US FDA had approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the ...

8/22/2023
CataractCornealDry EyeFundingGene TherapyIOLNewsletterPharmaRetinaSurgical
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C
Kriya Leads Latest Ophthalmic Fundraising with $150 Million in Series C

Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....

8/22/2023
Dry EyeGlaucomaNewsletterRefractiveRegulationRetina
US FDA Target Action Dates for Ophthalmic Drug Candidates, August to December 2023
US FDA Target Action Dates for Ophthalmic Drug Candidates, August to December 2023

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

8/18/2023
BreakingCataractDealsDry EyePharma
Eyenovia Licenses US Rights to Formosa’s Postsurgical Pain and Inflammation Candidate for $86 Million
Eyenovia Licenses US Rights to Formosa’s Postsurgical Pain and Inflammation Candidate for $86 Million

Taiwan-based Formosa Pharmaceuticals announced Aug. 16 that Eyenovia had licensed US rights to Formosa’s APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for inflammation and pain ...

8/4/2023
BreakingDry EyeFunding
Tarsus Prices $100 Million Public Offering of Common Stock
Tarsus Prices $100 Million Public Offering of Common Stock

Tarsus Pharmaceuticals announced July 31 that it had commenced an underwritten public offering of $100 million in common stock. The Irvine, California, company said it would grant the underwriters ...

7/28/2023
BreakingDry EyeRegulation
US FDA Approves Xdemvy Eye Drops from Tarsus for Demodex Blepharitis
US FDA Approves Xdemvy Eye Drops from Tarsus for Demodex Blepharitis

Tarsus Pharmaceuticals announced July 25 that the US FDA had approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the ...

7/28/2023
BreakingDry EyeGlaucomaIOLLaserRetinaRevenue
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others
Q2-2023 Ophthalmic Revenue Roundup for Roche, Novartis, J&J Vision, and Two Others

Swiss company Roche reported July 27 that Vabysmo sales for Q2-2023 were CHF 525 million ($606 million, converted July 27, 2023), a nearly 500 percent increase over CHF 88 million in Q2-2022. Roche...

7/25/2023
DealsDry EyeNewsletter
Deals for Xiidra, Blink Drops Show Saunders is Again Banking on Dry Eye
Deals for Xiidra, Blink Drops Show Saunders is Again Banking on Dry Eye

Brent Saunders seems to be betting that what was good for Allergan’s eye care business will be good for Bausch + Lomb. Dry eye treatments dominated Allergan’s eye care business during Saunders’ ten...

7/25/2023
Dry EyeGlaucomaNewsletterPresbyopiaRegulationRetina
US FDA Target Action Dates for Ophthalmic Drug Candidates
US FDA Target Action Dates for Ophthalmic Drug Candidates

The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...

7/25/2023
DealsDry EyeGlaucomaNewsletter
Santen Hands Over Rights for Eight Ophthalmic Pharma Products to Harrow, Visiox
Santen Hands Over Rights for Eight Ophthalmic Pharma Products to Harrow, Visiox

Japanese drugmaker Santen announced July 18 that Harrow had acquired US or Canadian commercial rights to seven of Santen’s branded eye drops, while Visiox Pharma had licensed US rights to Omlonti f...

7/25/2023
AllergyClinical TrialDry EyeGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2023
Clinical Trial Updates for Ophthalmic Candidates, July 2023

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more